North America Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)
Market Introduction
North America is largest market for gastroparesis with the US holding the largest market share followed by Canada. The growth in North America is characterized by rising prevalence of gastroparesis. In addition, aging population and growing prevalence of diabetes are also projected to offer lucrative opportunity for the growth of the North America gastroparesis market during the forecast period. In addition, extensive research in pharmaceutical and biotechnology companies is further expected stimulate the growth of gastroparesis market in North America.
Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis. Moreover, according to the world gastroenterology organization, there has been observed a rise in GI complications after COVID-19 symptoms. Patients with COVID-19 may complain of digestive symptoms such as poor appetite, nausea, vomiting, diarrhea, symptoms, or disease activity for pre-existing digestive diseases such as inflammatory bowel disease. However, according to a review of Diabetic Gastroparesis for the Community Pharmacist published in 2016, over 29.1 million people in the US have diabetes and have faced with the complications associated with the disease. Diabetes is the most common systemic disease that causes gastroparesis. Moreover, according to data published by National Center for Biotechnology Information (NCBI) in September 2020, nausea and vomiting from detailed consideration as symptoms of COVID?19 is surprising as it can be an early presenting symptom. Thus, there has been observed a rise in the sale of prokinetic agents and antiemetic agents. However, due to disruption in supply chain and governmental orders restricting certain activities in response to COVID-19, including changes in on-site operations to reduce manufacturing capacity and implement social distancing, reductions in suppliers’ ability to source, ship raw materials in alignment with demands, work stoppages, slowdowns, and delays, the market may show a slowdown.
Get more information on this report :
Market Overview and Dynamics
The gastroparesis market in North America is expected to grow from US$ 1,488.03 million in 2020 to US$ 2,032.27 million by 2027; it is estimated to grow at a CAGR of 4.6% from 2020 to 2027. Pharmaceutical and medical devices companies are focusing on R&D to develop new products for the treatment of gastroparesis. Academic institutes and research centers are also actively involved in drug discoveries. In December 2018, the International Foundation for Gastrointestinal Disorders announced launch of AGA-Shire Research Scholar Award to boost the studies in functional gastrointestinal (GI) and motility disorders. The organization announced the grant of ~US$ 300,000 along with other facilities. The findings of such studies are estimated to propel new product developments in the market, which would provide lucrative opportunities for the growth of the gastroparesis market players during the forecast period.
Key Market Segments
The North America gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The North America gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The North America gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the North America gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the North America gastroparesis market is segmented into US, Canada, and Mexico. US held the largest market share in 2019.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the gastroparesis market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Allergan Plc; ANI Pharmaceuticals, Inc.; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Cinrx Pharma, LLC (Cindome Pharma); EVOKE PHARMA; Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; NEUROGASTRX, INC.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD.
Reasons to buy report
- To understand the North America gastroparesis market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America gastroparesis market.
- Efficiently plan M&A and partnership deals in North America gastroparesis market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America gastroparesis market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Gastroparesis Market Segmentation
North America Gastroparesis Market - By Type
- Idiopathic
- Diabetic
- Post-surgical
- Others
North America Gastroparesis Market - By Drug Class
- Prokinetic Agents
- Botulinum Toxin Injections
- Antiemetic Agent
North America Gastroparesis Market – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
North America Gastroparesis Market - By Country
- US
- Canada
- Mexico
North America Gastroparesis Market - Company Profiles
- Allergan Plc
- ANI Pharmaceuticals, Inc.
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Cinrx Pharma, LLC (Cindome Pharma)
- EVOKE PHARMA
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- NEUROGASTRX, INC.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Gastroparesis Market – By Type
1.3.2 North America Gastroparesis Market – By Drug Class Type
1.3.3 North America Gastroparesis Market – By Distribution Channel
1.3.4 North America Gastroparesis Market – By Country
2. North America Gastroparesis Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Gastroparesis Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert Opinion
5. North America Gastroparesis Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Diabetes Mellitus Prevalence
5.1.2 Rising Geriatric Population
5.2 Market Restraints
5.2.1 Side Effects Associated with Gastroparesis Drugs
5.3 Market Opportunities
5.3.1 Rising Investments and Financial Assistance Related to Research
5.4 Future Trends
5.4.1 Gastric Electrical Stimulation Therapy Research Getting Popular
5.5 Impact Analysis
6. Gastroparesis Market – North America Analysis
6.1 North America Gastroparesis Market Revenue Forecast and Analysis
7. North America Gastroparesis Market Analysis – By Type
7.1 Overview
7.2 North America Gastroparesis Market Revenue Share, by Type (2019 and 2027)
7.3 Idiopathic
7.3.1 Overview
7.3.2 Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Diabetic
7.4.1 Overview
7.4.2 Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Post-Surgical
7.5.1 Overview
7.5.2 Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8. North America Gastroparesis Market Analysis – By Drug Class Type
8.1 Overview
8.2 North America Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
8.3 Prokinetic Agents
8.3.1 Overview
8.3.2 Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Botulinum Toxin Injection
8.4.1 Overview
8.4.2 Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Antiemetic Agents
8.5.1 Overview
8.5.2 Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9. North America Gastroparesis Market Analysis – By Distribution Channel
9.1 Overview
9.2 North America Gastroparesis Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Hospital Pharmacies
9.4.1 Overview
9.4.2 Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
10. North America Gastroparesis Market – Country Analysis
10.1 Overview
10.1.1 North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
10.1.2 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.1 US: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.2.2 US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.3 US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.2.4 US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.3 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.1 Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.3.2 Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.3 Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.3.4 Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
10.1.4 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.3 Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
10.1.4.4 Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on North America Gastroparesis Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Gastroparesis Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Gastroparesis Market, 2018-2020
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Evoke Pharma
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Allergan Plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 NEUROGASTRX, INC.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 ANI Pharmaceuticals, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Ipca Laboratories Ltd
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 CinRx Pharma, LLC (CinDome Pharma)
13.10.1 Business Description
13.10.2 Products and Services
13.10.3 Financial Overview
13.10.4 SWOT Analysis
13.10.5 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. US Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 2. US Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 3. US Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 4. Canada Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 5. Canada Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 6. Canada Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 7. Mexico Gastroparesis Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 8. Mexico Gastroparesis Market, by Drug Class Type – Revenue and Forecast to 2027 (USD Million)
Table 9. Mexico Gastroparesis Market, by Distribution Channel– Revenue and Forecast to 2027 (USD Million)
Table 10. Recent Inorganic Growth Strategies in the Gastroparesis market
Table 11. Recent Organic Growth Strategies In the Gastroparesis market
Table 12. Glossary of Terms, North America Gastroparesis Market
LIST OF FIGURES
Figure 1. North America Gastroparesis Market Segmentation
Figure 2. North America Gastroparesis Market Segmentation, By Country
Figure 3. North America Gastroparesis Market Overview
Figure 4. Idiopathic Segment Held Largest Share of North America Gastroparesis Market
Figure 5. US to Show Remarkable Growth During Forecast Period
Figure 6. North America PEST Analysis
Figure 7. North America Gastroparesis Market Impact Analysis of Drivers and Restraints
Figure 8. North America Gastroparesis Market – Revenue Forecast And Analysis – 2019- 2027
Figure 9. North America Gastroparesis Market Revenue Share, by Type (2019 and 2027)
Figure 10. North America Idiopathic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. North America Diabetic: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. North America Post-Surgical: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. North America Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. North America Gastroparesis Market Revenue Share, by Drug Class Type (2019 and 2027)
Figure 15. North America Prokinetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 16. North America Botulinum Toxin Injection: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. North America Antiemetic Agents: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. North America Gastroparesis Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 19. North America Retail Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. North America Hospital Pharmacies: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. North America Others: Gastroparesis Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. North America: Gastroparesis Market, by Key Country – Revenue (2019) (USD Million)
Figure 23. North America: Gastroparesis Market, by Country, 2019 & 2027 (%)
Figure 24. US: Pharmaceutical Drug Delivery market – Revenue and Forecast to 2027 (USD Million)
Figure 25. Canada: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. Mexico: Gastroparesis Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. Impact of COVID-19 Pandemic in North American Country Markets
Figure 28. Growth Strategies in the Gastroparesis Market, 2018-2020
- Allergan Plc
- ANI Pharmaceuticals, Inc.
- Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
- Cinrx Pharma, LLC (Cindome Pharma)
- EVOKE PHARMA
- Ipca Laboratories Ltd.
- Johnson and Johnson Services, Inc.
- NEUROGASTRX, INC.
- Pfizer Inc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America gastroparesis market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the gastroparesis market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution